ATP and cancer immunosurveillance
While intracellular adenosine triphosphate (ATP) occupies a key position in the bioenergetic
metabolism of all the cellular compartments that form the tumor microenvironment (TME) …
metabolism of all the cellular compartments that form the tumor microenvironment (TME) …
Chemotherapeutic drug-induced immunogenic cell death for nanomedicine-based cancer chemo–immunotherapy
M Jiang, J Zeng, L Zhao, M Zhang, J Ma, X Guan… - Nanoscale, 2021 - pubs.rsc.org
Chemotherapy has been a conventional paradigm for cancer treatment, and multifarious
chemotherapeutic drugs have been widely employed for decades with significant …
chemotherapeutic drugs have been widely employed for decades with significant …
Thiostrepton induces ferroptosis in pancreatic cancer cells through STAT3/GPX4 signalling
W Zhang, M Gong, W Zhang, J Mo, S Zhang… - Cell Death & …, 2022 - nature.com
Ferroptosis is a new form of regulated cell death that is mediated by intracellular iron and
ester oxygenase, and glutathione-dependent lipid hydroperoxidase glutathione peroxidase …
ester oxygenase, and glutathione-dependent lipid hydroperoxidase glutathione peroxidase …
HMGB1 in the interplay between autophagy and apoptosis in cancer
Lysosome-mediated autophagy and caspase-dependent apoptosis are dynamic processes
that maintain cellular homeostasis, ensuring cell health and functionality. The intricate …
that maintain cellular homeostasis, ensuring cell health and functionality. The intricate …
Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review
J Zhai, X Gu, Y Liu, Y Hu, Y Jiang… - Frontiers in …, 2023 - frontiersin.org
As traditional strategies for cancer treatment, some chemotherapy agents, such as
doxorubicin, oxaliplatin, cyclophosphamide, bortezomib, and paclitaxel exert their anti-tumor …
doxorubicin, oxaliplatin, cyclophosphamide, bortezomib, and paclitaxel exert their anti-tumor …
[HTML][HTML] Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better
M Zheng - Journal for immunotherapy of cancer, 2022 - ncbi.nlm.nih.gov
Background Recently, the US Food and Drug Administration (FDA) has approved immune
checkpoint blockade (ICB) for treating cancer patients with tumor mutation burden (TMB)> …
checkpoint blockade (ICB) for treating cancer patients with tumor mutation burden (TMB)> …
Autophagy in health and disease: From molecular mechanisms to therapeutic target
Macroautophagy/autophagy is an evolutionally conserved catabolic process in which
cytosolic contents, such as aggregated proteins, dysfunctional organelle, or invading …
cytosolic contents, such as aggregated proteins, dysfunctional organelle, or invading …
Immunogenic cell death (ICD) enhancers—Drugs that enhance the perception of ICD by dendritic cells
The search for immunostimulatory drugs applicable to cancer immunotherapy may profit
from target‐agnostic methods in which agents are screened for their functional impact on …
from target‐agnostic methods in which agents are screened for their functional impact on …
Engineering oxaliplatin prodrug nanoparticles for second near‐infrared fluorescence imaging‐guided immunotherapy of colorectal cancer
Q Zhu, F Sun, T Li, M Zhou, J Ye, A Ji, H Wang, C Ding… - Small, 2021 - Wiley Online Library
Colorectal cancer (CRC) ranks as the third common and the fourth lethal cancer type
worldwide. Immune checkpoint blockade therapy demonstrates great efficacy in a subset of …
worldwide. Immune checkpoint blockade therapy demonstrates great efficacy in a subset of …
[HTML][HTML] IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanisms
Q Wu, AL Tian, B Li, M Leduc, S Forveille… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background Pharmacological autophagy enhancement constitutes a preclinically validated
strategy for preventing or treating most major age-associated diseases. Driven by this …
strategy for preventing or treating most major age-associated diseases. Driven by this …